Mostrar el registro sencillo del ítem
Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab ACT-AXIS study
dc.contributor.author | Corominas, H. | |
dc.contributor.author | Alegre, C. | |
dc.contributor.author | Narvaez, J. | |
dc.contributor.author | Fernandez-Cid, C. M. | |
dc.contributor.author | Torrente-Segarra, V. | |
dc.contributor.author | Rodríguez Gómez, Manuel | |
dc.contributor.author | Pan, F. M. | |
dc.contributor.author | Morla, R. M. | |
dc.contributor.author | Martinez, F. J. R. | |
dc.contributor.author | Gomez-Centeno, A. | |
dc.contributor.author | Ares, L. L. | |
dc.contributor.author | Molina, R. G. | |
dc.contributor.author | Gonzalez-Albo, S. P. | |
dc.contributor.author | Dalmau-Carola, J. | |
dc.contributor.author | Perez-Garcia, C. | |
dc.contributor.author | Barbazán Alvarez, Ceferino Tomas | |
dc.contributor.author | Ercole, L. | |
dc.contributor.author | Terrancle, M. A. | |
dc.date.accessioned | 2022-01-28T11:51:29Z | |
dc.date.available | 2022-01-28T11:51:29Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0025-7974 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/31261500 | es |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617279/pdf/medi-98-e15947.pdf | es |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/31261500 | es |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617279/pdf/medi-98-e15947.pdf | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16000 | |
dc.description.abstract | To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 +/- 12.5 years, disease duration 8.7 +/- 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 +/- 4.0 (P < .001). Mean Disease Activity Index score (DAS28) decreased from 5.5 +/- 1.0 at baseline to 2.7 +/- 1.3 (P < .001) at week 24. Mean change in Functional Assessment of Chronic Illness Therapy score was -5.4 +/- 11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep, and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively.Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue variance with the use of TCZ in RA patients. | en |
dc.language.iso | eng | es |
dc.rights | Atribución-NoComercial 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject.mesh | Tumor Necrosis Factor-alpha | * |
dc.subject.mesh | Sleep | * |
dc.subject.mesh | Retreatment | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Antibodies | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Antirheumatic Agents | * |
dc.subject.mesh | C-Reactive Protein | * |
dc.subject.mesh | Prospective Studies | * |
dc.subject.mesh | Depression | * |
dc.subject.mesh | Fatigue | * |
dc.subject.mesh | Arthritis | * |
dc.title | Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab ACT-AXIS study | en |
dc.type | Artigo | es |
dc.contributor.authorcorp | Act-Axis Study Group | |
dc.authorsophos | Corominas, H.;Alegre, C.;Narvaez, J.;Fernandez-Cid, C. M.;Torrente-Segarra, V.;Gomez, M. R.;Pan, F. M.;Morla, R. M.;Martinez, F. J. R.;Gomez-Centeno, A.;Ares, L. L.;Molina, R. G.;Gonzalez-Albo, S. P.;Dalmau-Carola, J.;Perez-Garcia, C.;Alvarez, C. B.;Ercole, L.;Terrancle, M. A.;Grp, Act-Axis Study | |
dc.identifier.doi | 10.1097/md.0000000000015947 | |
dc.identifier.pmid | 31261500 | |
dc.identifier.sophos | 33195 | |
dc.issue.number | 26 | es |
dc.journal.title | MEDICINE | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Reumatoloxía | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Reumatoloxía | es |
dc.rights.accessRights | openAccess | es |
dc.subject.decs | sueño | * |
dc.subject.decs | resultado del tratamiento | * |
dc.subject.decs | estudios prospectivos | * |
dc.subject.decs | factor de necrosis tumoral alfa | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | depresión | * |
dc.subject.decs | humanos | * |
dc.subject.decs | fatiga | * |
dc.subject.decs | anticuerpos | * |
dc.subject.decs | retratamiento | * |
dc.subject.decs | antirreumáticos | * |
dc.subject.decs | proteína C reactiva | * |
dc.subject.decs | artritis | * |
dc.subject.keyword | CHUO | es |
dc.subject.keyword | CHUVI | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 98 | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 4.0 Internacional
![](/xmlui/themes/Mirage2//images/final_lines.png)